Title: Akt regulates axon wrapping and myelin sheath thickness in the PNS

Abbreviated title: Akt regulates PNS axon wrapping and myelination

Enric Domènech-Estévez1,2,3,§, Hasna Baloui1,2,3,§, Xiaosong Meng1,2, Yanqing Zhang1,2, Katrin Deinhardt4, Jeff L. Dupree5, Steven Einheber6, Roman Chrast3, James L. Salzer1,2,*

1 Neuroscience Institute and 2 Departments of Neuroscience and Physiology and Neurology, NYU-Langone Medical Center, New York, NY 10016 USA
3 Department of Neuroscience and Department of Clinical Neuroscience, Karolinska Institutet, 17177 Stockholm, Sweden
4 Centre for Biological Sciences, Faculty of Natural & Environmental Sciences, University of Southampton, Southampton, SO17 1BJ, UK
5 Department of Anatomy and Neurobiology, Virginia Commonwealth University Medical Campus, Box 980709, Richmond, VA 23298-0709, USA
6 Department of Medical Laboratory Sciences, Hunter College, CUNY, New York, NY 10010, USA

§ Those authors contributed equally to the work

* Corresponding Authors: Enric Domènech-Estévez, PhD, Retzius väg 8, 17177 Stockholm, Sweden +46852486542 enric.domenech-estevez@ki.se, and James L. Salzer, MD, PhD, 550 First Avenue, New York, NY, 10016 USA +12122630758 james.salzer@nyumc.org.

Number of pages: 38

Number of figures: 9

Number of words: Abstract (250), Introduction (614), Discussion (1618).

Conflicts of interest: The authors declare no competing financial or any other conflict of interests.
Acknowledgements: This work was supported by NIH grant NS26001 (JLS) and the NYU Cancer Institute Center support Grant NIH/NCI 5P30CA16087-31. EDE was partially funded by the Spanish Ministerio de Educación y Ciencia-Fulbright commission. EDE, HB and RC are supported by Strategic Research Area Neuroscience (StratNeuro) program. We thank Eric Roth and Feng-Xia Liang (NYU) and Kjell Hultenby and Eva Idsund (KI) for assistance with EM of mouse neural tissue, and Dr. Teresa Milner (Weill Cornell Medical College) for assistance with EM of the cocultures. We thank Dr. Frédéric Schütz (University of Lausanne) for his support with statistics.

ABSTRACT: The signaling pathways that regulate myelination in the peripheral nervous system (PNS) remain poorly understood. Phosphatidylinositol-4,5-bisphosphate 3-kinase 1A (PI3K), activated in Schwann cells by neuregulin and the extracellular matrix, has an essential role in the early events of myelination. Akt/PKB, a key effector of PI3K, was previously implicated in CNS, but not PNS myelination. Here we demonstrate that Akt plays a crucial role in axon ensheathment and in the regulation of myelin sheath thickness in the PNS. Pharmacological inhibition of Akt in DRG neuron-Schwann cell cocultures dramatically decreased MBP and P0 levels and myelin sheath formation without affecting expression of Krox20/Egr2, a key transcriptional regulator of myelination. Conversely, expression of an activated form of Akt in purified Schwann cells increased expression of myelin proteins, but not Krox20/Egr2, and the levels of activated Rac1. Transgenic mice expressing a membrane-targeted, activated form of Akt under control of the 2',3'-cyclic nucleotide 3'-phosphodiesterase (CNP) promoter, exhibited thicker PNS and CNS myelin sheaths, and PNS myelin abnormalities such as tomacula and myelin in/outfoldings centered around the paranodes and Schmidt Lanterman incisures. These effects were corrected by rapamycin treatment in vivo. Importantly, Akt activity in the transgenic mice did not induce myelination of non-myelinating
Schwann cells in the sympathetic trunk or Remak fibers of the dorsal roots although, in those structures, they wrapped membranes redundantly around axons. Together, our data indicate that Akt is crucial for PNS myelination driving axonal wrapping by unmyelinated and myelinated Schwann cells and enhancing myelin protein synthesis in myelinating Schwann cells.

Key words: Akt; Schwann cell; myelin; transgenic; wrapping; mTOR

**SIGNIFICANCE STATEMENT:** Although the role of the key serine/threonine kinase Akt in promoting CNS myelination has been demonstrated, its role in the PNS has not been established and remains uncertain. This work reveals that Akt controls several key steps of the PNS myelination. Firstly, its activity promotes membrane production and axonal wrapping independent of a transcriptional effect. In myelinated axons, it also enhances myelin thickness through the mTOR pathway. Finally, sustained Akt activation in Schwann cells leads to hyper/dysmyelination, mimicking some features present in neuropathies, such as Hereditary Neuropathy with Liability to Pressure Palsies or demyelinating forms of Charcot-Marie-Tooth disease. Together, these data demonstrate the role of Akt in regulatory mechanisms underlying axonal wrapping and myelination in the PNS.
INTRODUCTION

Formation of the myelin sheath in the PNS is among the most dramatic examples of axon-glial interactions (Mirsky et al., 2008). Schwann cells are intimately associated with axons and adopt distinct fates as either myelinating or non-myelinating, i.e. Remak Schwann cells. These two Schwann cell phenotypes are distinguished by both their morphological relationship with the axon and by different transcriptional profiles. A number of axonal signals have been implicated in the regulation of the Schwann cell phenotype, including ADAM22 which binds Lgi4 secreted by the Schwann cell and the axonal growth factor neuregulin1 type III (Nrg1III), which activates the ErbB2/ErbB3 heterodimer on Schwann cells (see (Kidd et al., 2013; Nave and Werner, 2014; Monk et al., 2015; Salzer, 2015) for recent reviews).

Nrg1, in particular, controls virtually all aspects of the Schwann cell lineage including initial gliogenesis, proliferation, ensheathment and myelination of axons. High levels of Nrg1III on the axonal membrane provide a threshold signal for the induction of myelination and regulate the thickness of the myelin sheath (Michailov et al., 2004; Taveggia et al., 2005; Nave and Salzer, 2006). Nrg1III activates the Mitogen-activated protein kinase (MAPK), Phosphatidylinositol 3-kinase 1A (PI3K) and Phospholipase C gamma (PLCγ) pathways, each of which has been implicated as essential for proper myelination (Newbern and Birchmeier, 2010). The precise roles of these signaling pathways in the transcriptional and morphogenetic events of myelination however, remain to be established.

Previous studies using in vitro models demonstrated that PI3K activation is necessary for proper PNS myelination (Maurel and Salzer, 2000; Ogata et al., 2004). A promyelinating role of PI3K was further supported by studies in mice in which the Phosphatase and tensin homolog (PTEN), a PI-3 phosphatase, was conditionally inactivated in glia thereby driving sustained activation of PI3K (Goebbel et al., 2010). Loss of PTEN function in these mice, as well as inactivation of its interactor Dlg1 (Cotter et al., 2010; Goebbel et al., 2010; Noseda et
al., 2013) results in PNS hypermyelination and increased wrapping of small caliber axons by Schwann cells.

The serine/threonine kinase Akt has been thought to be the major PI3K effector during myelination, particularly in the CNS (Flores et al., 2008). Mice expressing a constitutively active, phospho-mimetic form of Akt under control of the proteolipid protein (PLP) promoter, exhibit hypermyelination in the CNS. Surprisingly the PNS of these mice was not hypermyelinated (Flores et al., 2008) leaving open the question of the role of Akt in Schwann cells.

Here we use loss and gain of function approaches to provide direct evidence that Akt promotes PNS myelination and axonal wrapping. Pharmacological inhibition of Akt activity abrogates myelin formation in vitro, without affecting the levels of Krox20/Egr2, a transcription factor crucial for PNS myelination (Zorick et al., 1996; Decker et al., 2006). Conversely, mice that express a myristoylated, constitutively active Akt transgene in myelinating glia under control of the 2',3'-cyclic nucleotide 3'-phosphodiesterase (CNP) promoter, exhibit hypermyelination in the PNS and CNS. No conversion of axons from an unmyelinated to a myelinated fate was observed in these mice, although aberrantly, hyperwrapped Remak fibers are common. These mice also exhibit focal hypermyelination, a pathological hallmark of some models of peripheral neuropathies (Adlkofer et al., 1997; Bolino et al., 2004; Tersar et al., 2007; Robinson et al., 2008). They develop myelin defects similar to those described in a model of tomaculous neuropathy (Goebbels et al., 2012), which can be corrected with rapamycin treatment. Finally, Akt activation in vitro results in activation of Rac1, previously implicated in myelin sheath wrapping (Thurnherr et al., 2006; Benninger et al., 2007; Nodari et al., 2007).

Together, these data indicate that Akt promotes Schwann cell wrapping and myelination via multiple distinct pathways involving mTOR and Rac1 activation.
MATERIAL AND METHODS

Generation of the CNP-MyrAkt and CNP-AktDD transgenic mice:

cDNAs for MyrAktHA and HAAktDD were kindly provided by Dr. Thomas Franke (New York University) (Franke et al., 1995; Matsui et al., 1999). A plasmid containing the CNP promoter (Gravel et al., 1998) was kindly provided by Dr. Karen Chandross (Sanofi).

CNP-MyrAkt: The vector containing the CNP cassette was digested with BamHI and dephosphorylated with CIP phosphatase. MyrAktHA was released using BamHI/BglII digestion and inserted after the CNP promoter. The construct CNP-MyrAktHA was then released by sequential digestion AseI/BtsI. DNA was purified by gel extraction (QIAquick gel extraction, Qiagen), salt elution (Elutip-D, Whatman #10462615), and ethanol precipitation.

CNP-AktDD: The vector containing the CNP cassette was digested with AfeI/BamHI. An initial ClaI digestion followed by Kleenow filling was done in AktDD cDNA. Afterwards, BamHI digestion was performed. The insert was ligated after the CNP promoter and then released using AseI/MluI digestion. The DNA was purified as described for the CNP-MyrAktHA construct.

The constructs were injected into FVB females in the NYUMC Transgenic Mouse Core. Positive founders were PCR identified over tail DNA using the primers TgAktFd (5'-TCT GAG GAT GCC AAG GAG AT-3') and TgAktRev (5'-GGG CGA TCG AGT GAA TTG TA-3'). To ensure the specificity of the PCR product, one of the primers was designed to match a portion of plasmid inserted with the cassette. Founders were backcrossed to C57Bl6 wild-type mice for at least five generations before analysis; sibling littermates were used in all analyses. All experiments were carried out with the L1MyrAkt line, but a similar phenotype was observed in the L2MyrAkt line. In some cases (AktDD), analysis was done on founders because of infertility. All experiments with mice were performed in accordance with the legal requirements of NYU.
Akt knockouts: Akt1KO (Cho et al., 2001a) and Akt2KO (Cho et al., 2001b) were obtained from The Jackson Laboratory (stock numbers 004912 and 006966, respectively). Akt3KO (Easton et al., 2005) were obtained from Dr. Morris J. Birnbaum (University of Pennsylvania) under MTA agreement.

Materials. Antibodies to specific proteins were obtained from the following companies:

- Cell Signaling Technology (total Akt1-3, pAkt Ser473, pAkt Thr308, total c-Jun and p c-Jun Ser73, total S6RP and pS6RP Ser235/236, total GSK3b and pGSK3b Ser9, rabbit HA),
- Millipore (rabbit MBP, chicken P0, chicken MBP, mouse NeuN), Covance (mouse SMI 94 MBP, chicken Neurofilament), Sigma (mouse tubulin, rabbit anti-EHS laminin, rabbit actin, mouse HA.11), Rabbit anti-Krox20 and rabbit anti-Oct6 were kindly provided by Dr. Dies Mejer (University of Edinburg), guinea pig anti-CASPR by Dr. M. Bhat (University of North Carolina) and guinea pig anti-Oct6 antibody was provided by Dr. Jeremy Dasen (New York University).

Secondary antibodies conjugated to rhodamine, AMCA or Alexa 488 were obtained from Jackson ImmunoResearch.

Immunoblotting. Tissues were lysed in 2% SDS, 25 mM Tris, 95 mM NaCl and 10 mM EDTA buffer with protease inhibitors (complete Mini EDTA-free tablets, Roche 11836170001) and phosphatase inhibitors (PhosSTOP, Roche 04906837001). Nerves were sonicated 10 seconds at the lowest intensity. Fifteen to fifty micrograms of protein was loaded on 12.5% SDS-PAGE gel. After transfer on nitrocellulose membrane (Whatman #10402580), and incubation with primary antibodies, the blots were developed and quantified by using infrared secondary antibodies and software from Odyssey Imager (LI-COR Biosciences).

Lentivirus production and infection: Doxycycline inducible lentiviruses were created in the pSLIK-Hygromycin vector as per the manufacturer’s instructions (Invitrogen, Gateway Technology with clonase II). Confluent 293FT cells were lipofected with LipoD293 reagent (SignaGen laboratories SL 100668). A triple lipofection with Δ8.9 (4 µg), VSVG (6 µg) and
MyrAkt-HA or green fluorescent protein (GFP) (5 µg) was performed. Supernatant was collected 48 hours after lipofection and used to infect Schwann cells. Infected cells were selected for 9 days with 200 µg/ml of hygromycin (Hygrogold, Invivogen # ant-hg-1) prior to use in experiments. Induction was performed by adding doxycycline (2 µg/ml) to the culture media for four days.

**Dorsal root ganglia neuron-Schwann cell cocultures:** Rat neuron-Schwann cell cocultures were performed as previously described (Taveggia et al., 2005).

Rapamycin and LY294002 (LY) were obtained from LC Laboratories (R-5000 and L-7962 respectively). Perifosine (Pf) was obtained from Cayman Chemical Company (10008112). Drugs (20 µM of LY294002 or 20 µM of perifosine) were added 24 hours prior to and then continued after switching the cocultures to myelinating media.

**Rac1 and cdc42 pull down:** Schwann cells were infected with inducible MyrAkt and processed as described above. Doxycycline was then added to the proliferative Schwann cell media for 4 days and Rac1 and cdc42 activities were analyzed as previously described (Deinhardt et al., 2011). To generate the respective plots, values of active GTPase levels were divided by the total GTPase levels after actin normalization, which was used as a loading control.

**Cell culture immunofluorescence and immunohistochemistry:** Mice were fixed via transcardial perfusion with 4% PFA. Dissected brains were postfixed in 4% PFA overnight at 4°C, cryoprotected by immersion in 20% sucrose in PBS. 40 µm floating sections were prepared on a cryostat. Cells were fixed 15 minutes with 4% PFA. Tissue and cells were processed for immunostaining as previously described (Zanazzi et al., 2001). For Fig. 4D, adult mouse sciatic nerve and dorsal root ganglia were fixed in 1% PFA and embedded for cryosectioning and processed for immunofluorescence.
Teased fibers: Sciatic nerves were harvested from six-months old animals and fixed in 2% PFA for four hours. After a 10 minute wash in 30 mM glycine PBS, the fibers were teased on a glass slide using needles, and dried overnight. Slides were kept at -80°C until needed. Tissue was permeabilized 20 minutes in cold methanol prior to staining as described above. Then, the same protocol as used for cell staining was followed.

Proliferation assay: 50,000 rat Schwann cells were seeded into established, purified rat neuron cultures for 24h prior to adding the drugs (Pf and LY) to the media in a final volume of 400 µl. Twenty hours later, cocultures were exposed to media containing the drugs and 20 µM of bromodeoxyuridine (BrdU) for 4 hours. Cells were then fixed in PFA 4%, permeabilized with methanol and treated as previously described (Maurel and Salzer, 2000). The ratio of BrdU positive:Hoechst positive cells were calculated from non-overlapping pictures of the whole coverslip. Four independent sets of experiments were performed (n=4), and from each of them, three independent coverslips were screened.

RNA extraction and quantitative real-time PCR: Total RNA was isolated using a RiboPure Kit (Ambion). cDNA was generated from 250-600 ng of total RNA by AMV Reverse Transcriptase (Promega) and the transcripts were detected and amplified by quantitative real-time PCR in a LightCycler machine (Roche) following the manufacturer’s instructions. GAPDH was used as internal control. Real-time PCR conditions were as follows: 1 cycle 10’ 95°C, 50 cycles (30” 95°C, 30” 56°C, 30” 72°C), 1 cycle 1’ 95°C, 30” 55°C and 30” 95°C. Primers:

- MAG Fd 5’-ACC TTG CAG TTC GAG GGT TA-3’, MAG Rev 5’-ACA GAG CAG GCT GAC ATG-3’;
- MBP Fd 5’-ACT ACC CAC TAC GGC TCC CT-3’, MBP Rev 5’-GGG TGT ACG AGG TGT CAC AA-3’;
- Krox20 Fd 5’-GTT GGT TTC ACC ATG TCC CT-3’, Krox20 Rev 5’-CCA CAG AGG TGG TGA CAC AA-3’;
- GAPDH Fd 5’-AGA AGA CTG TCG TGG ATG GCC C-3’, GAPDH Rev 5’-AGA AGA CTG TCG TGG ATG GCC C-3’;
- MPZ Fd 5’-CCG GTC AGC TCT GGG ATG ACC TT-3’, MPZ Rev 5’-CTG GGA GCG CAC AGC ACC AT-3’.
Rapamycin treatment in vivo: The drug was dissolved in vehicle solution containing 5% polyethylene glycol 400, 5% Tween 80, and 8% ethanol. Rapamycin (7.5 mg/kg) or vehicle was administered intraperitoneally for 5 days a week during 8 weeks. Mice were treated beginning at 5 weeks of age and were weighed every week to adjust the treatment. A total of 21 mice were treated, 7 WT and 7 Tg with vehicle, and 7 Tg with rapamycin. Two independent rounds of treatment were done for morphometric and WB analyses.

Electronic microscopy and morphometric analysis: Control and treated three weeks old myelinating cocultures grown on collagen-coated glass coverslips were rinsed in PBS and fixed overnight at 4° C in 2% glutaraldehyde in 0.1 M phosphate buffer pH 7.0 (0.1 M PB). After gently removing the fixed cultures from the coverslips they were washed in 0.1 M PB, incubated in 2% osmium tetroxide in 0.1 M PB for 1 hour and processed for flat embedding in EMbed 812 (Electron Microscopy Sciences, Fort Washington, PA). Ultrathin sections were counterstained with uranyl acetate and Reynold's lead citrate and examined on a Philips (Eindhoven, The Netherlands) CM10 electron microscope. For the in vivo analysis, mice were fixed via transcardial perfusion with 4% paraformaldehyde, 2.5% glutaraldehyde and 0.1 M sucrose in 0.1 M PB, pH7.4. Sciatic nerves, spinal roots (L4 level), optic nerve and sympathetic tract were collected. Tissues embedded in EMbed 812 were sectioned on a Leica UCT ultramicrotome at a thickness of 1 µm and stained with a solution of 1% toluidine blue. For TEM, tissues embedded in EMbed 812 were sectioned on a Leica UC6 ultramicrotome at a thickness of 90 nm and placed on copper slotted grids or occasionally on mesh grids. Sections were stained with 3% uranyl acetate in 50% methanol for 20 minutes followed by lead citrate for 5 minutes. Grids were viewed on a Philips CM12 Tungsten Emission TEM at 120kV and imaged with a GATAN 4k x 2.7k digital camera.

For g-ratios, non-overlapping digitized images of fiber cross-sections from dorsal roots were obtained and analyzed using Nikon software. G ratio were calculated by dividing the axon
diameter by the total fiber diameter. G ratios were determined exclusively in the dorsal root due to their mix of small and large caliber axons. All fibers with myelin abnormalities or fixation artifacts were excluded from analysis. Three animals per genotype were used for the WT/MyrAkt data (Fig. 5D, E), and four animals per genotype and conditions were quantified for the rapamycin experiments (Fig. 9D). The number of axons per Remak bundle and the number of axons in Schwann cell pockets were counted in the sciatic nerve by using Image J software (National Institute of Health). The number of axons per 100 µm² and the total number of myelin abnormalities per sciatic nerve were determined from merged micrographs of thin sciatic nerve sections (400X), assembled with Adobe Photoshop (Fig. 9C). Overlapping digitized images (400X) from thin sections of dorsal and ventral roots were merged to determine the total number of myelinated axons in Fig. 6F.

Statistical analysis: The unpaired two-tailed T-test was performed on all data to assess significance. In each case, the standard error of the mean (SEM) is shown in the plots although only the upper part of the SEM is depicted. Each n represents a different independent experiment or animal. Significance was considered for $p < 0.05$ (*) and $p < 0.01$ (**).

RESULTS

Akt activity is required for myelination and axon sorting

To address a role of Akt in myelination, we first examined Akt null mice for any abnormalities in the peripheral nerves. There are three Akt genes (Akt1, Akt2 and Akt3), each with different tissue expression and substrate affinities (Easton et al., 2005; Tschopp et al., 2005; Franke, 2008; Leavens et al., 2009). Western blot analysis revealed that Akt1 is expressed in both neurons and Schwann cells whereas Akt2 and Akt3 are primarily expressed by Schwann cells and neurons, respectively (Fig. 1A). We next examined whether mice deficient in each of these Akt isoforms exhibit myelination defects by comparing sciatic nerves
from two month-old WT vs. knockout mice via semithin sections. There were no obvious
differences between the knockout mice and their wild type littermates in terms of nerve size or
the extent of myelination (Fig. 1B). No obvious abnormalities of myelinated fibers or Remak
bundles were evident on inspection of electron micrographs of the Akt mutants vs. their WT
littermates (Fig. 1Ba-f). The overall preservation of morphology in individual mutants likely
reflects compensation by remaining Akt isoforms.

We therefore undertook to inhibit all Akt activity with the pharmacological inhibitor
perifosine (Pf), an alkylphospholipid that impairs Akt by blocking its PH domain (Hennessy et
al., 2007; Gills and Dennis, 2009). In parallel, we inhibited PI3K activity with the LY294002 (LY)
inhibitor (Vlahos et al., 1994; Maurel and Salzer, 2000). Treatment of cocultures with each
inhibitor blocked nearly all myelin formation (Fig. 2A, B). In agreement, expression levels of
MBP and P0 protein (Fig. 2C, D) were significantly reduced in the Pf-treated and nearly absent
in the LY-treated cocultures. mRNA levels for MBP were dramatically reduced in the presence
of either drug whereas the effect of Pf on P0 was more modest, perhaps due to its higher basal
levels of expression (Fig. 2E). Unexpectedly, Oct6/SCIP and Krox20, key transcription factors
for PNS myelination, were robustly expressed in the nuclei of the Pf-treated Schwann cells
(Fig. 2A) and the levels of Krox20 protein (Fig. 2C, D) and mRNA (Fig. 2E) were unaffected.
These results suggest that the promyelinating effects of Akt are independent of Krox20. In
contrast to Pf, cocultures treated with LY did not express any Krox20 protein or mRNA (Fig. 2A,
C-E).

There was no effect of Pf on Schwann cell proliferation in the cocultures (Fig. 2F), in
further contrast to LY (Fig. 2F), which is known to inhibit Schwann cell proliferation induced by
axonal neuregulin (Maurel and Salzer, 2000). Consequently Schwann cell numbers were
markedly reduced in the LY- but not the Pf-treated cocultures (Fig. 2A). To determine whether
reduced numbers of Schwann cells in the LY treated cocultures contributed to the limited
expression of Krox20, we seeded a 5 fold excess of SCs prior to treatment with LY. No significant Krox20 or myelin protein expression was detected under these conditions (data not shown) indicating that the effects of LY are independent of an effect on cell numbers.

Our results confirm that PI3K activity is crucial for myelination \textit{in vitro} and reveal that its effector Akt controls myelin mRNA and protein expression in the PNS, independent of Krox20 regulation. The data also suggests that PI3K regulates Schwann cell proliferation and the expression of myelin transcription factors by mechanisms independent of Akt.

Ultrastructural analysis of these cultures further revealed that Pf and LY differentially affected Schwann cell ensheathment. Schwann cells in the Pf-treated cultures partially surrounded the axons, although did not completely wrap most of them (Fig. 2G). In contrast, in the LY treated cocultures, Schwann cell were apposed to but completely failed to ensheathe axons (Fig. 2G). Myelination was dramatically reduced by both treatments.

\textbf{Activated Akt enhances myelin protein and mRNA expression \textit{in vitro} independent of Krox20 levels}

We next examined whether Akt activity is not only necessary, but is also sufficient for triggering myelination. We used a lentiviral vector to express a doxycycline-inducible, HA-tagged myristoylated Akt (MyrAkt) in cultured Schwann cells. MyrAkt is expressed and active at the membrane independent of PIP3 concentrations. After infection, Schwann cell cultures were maintained on media containing ascorbate in the presence or absence of doxycycline for four days. Schwann cells infected with a doxycycline-inducible lentivirus encoding GFP, which served as a control, displayed no increase of myelin proteins or Krox20 (Fig. 3A). In general, the expression of activated Akt increased MAG and P0 protein and mRNA levels; this increase was significant in the case of MAG protein (Fig. 3B-D). Interestingly, Krox20 protein levels were slightly reduced and mRNA levels unchanged despite the induction of myelin proteins following
MyrAkt expression (Fig. 3B-D) suggesting these changes were independent of Krox20 regulation.

**Transgenic expression of activated Akt isoforms results in PNS hypermyelination**

To assess the role of Akt *in vivo*, we generated transgenic mice expressing HA-tagged MyrAkt or AktDD in myelinating glia under control of 2', 3'-cyclic nucleotide 3'-phosphodiesterase (CNP) promoter elements (Fig. 4A). Both Akt1 isoforms are constitutively active as the result of either being targeting to the membrane (MyrAkt) or via mutations of two phosphorylation sites (Thr308 and Ser473) to aspartate that mimic the activated state (AktDD) (Fig. 4A). We generated four CNP-MyrAkt positive founders and three transgenic CNP-AktDD founders. All four CNP-MyrAkt lines exhibited enlarged brains, optic and sciatic nerves; this was evident at several months of age and quite pronounced at one year of age (Fig. 4C). Due to breeding problems with the CNP-AktDD mice, only founders were analyzed. Only one of the CNP-AktDD founder mice exhibited a hypermyelinated phenotype, evident in the sciatic nerves (Fig. 5B).

Two of the CNP-MyrAkt that transmitted the transgene were analyzed in detail. In each case, transgenic mice were phenotypically indistinguishable from wild type littermates until approximately one year of age when they developed limited motility and breathing difficulties. In agreement with the expression of CNP (Chandross et al., 1999), the HA-tagged transgene was detected in transgenic sciatic nerves at P0.5, the earliest time point examined (Fig. 4B). Its expression increased during active myelination (P10 to P21) and remained robust into adulthood. Expression of the HA-tag was also detectable in DRGs directly isolated from E13.5 embryos (Fig. 4B), likely reflecting the presence of glial/satellite cells in these DRGs. In agreement, staining of adult DRGs and sciatic nerves was largely if not exclusively confined to glial cells (Fig. 4D).
Transgenic mice were hypermyelinated in both the CNS and PNS. CNS hypermyelination was evident by increased MBP staining on coronal sections and an increase in the size of the corpus callosum (Fig. 4E). Both the sciatic and optic nerves were also markedly expanded in diameter, based on toluidine blue staining of semi-thin sections (Fig. 5A). Electron micrographs showed that individual nerve fibers were hypermyelinated (Fig. 5B) evident as an increase in the number of myelin lamellae; myelin periodicity was unaffected (Fig. 5C). G-ratios were significantly decreased in 5 month-old transgenic mice (Figs. 5D, E). Hypermyelination was most pronounced in small caliber axons, i.e. those less than 2 microns in diameter in both the dorsal roots (Fig. 5D, E) and ventral roots (data not shown).

The total numbers of Hoechst positive cells in the ventral and dorsal roots were counted. No significant differences in cell numbers were detected in four transgenic roots as compared to roots from their WT littermates (Fig. 5F). These results suggest that in our system, tissue hypertrophy results from an Akt-mediated increase in myelin and, perhaps, increased extracellular matrix production, rather than increased numbers of cells.

Akt activation promotes Schwann cell wrapping but does not alter the ensheathment fate of axons

Remak fibers were also affected in the CNP-MyrAkt transgenic mice. In wild type nerves as expected, small caliber axons were enclosed within individual pockets of a single unmyelinated Schwann cell (Fig. 6A). In contrast, in the transgenic nerves, multiple layers of Schwann cell membrane frequently wrapped small caliber axons. High power micrographs revealed these wrapped membranes were non-compacted (inset in 6A, middle panel); pockets with a normal structure that enclosed axons were absent (Fig. 6AI). Transgenic Schwann cell pockets sometimes contained collagen fibers rather than axons; these were more frequent in older animals and were surrounded by basal lamina (Fig. 6All). Indeed, Schwann cell
processes were also seen surrounded by basal lamina without any axonal contact suggesting that Akt can drive Schwann cell basal lamina formation in the absence of axonal signals (Fig. 6BI). Some pockets were formed even without any detectable content (Fig. 6BII) and, in such cases, a reversed orientation of the basal lamina was detected, secreted inside the empty pocket (Fig. 6BII). Finally, there was a trend to enhanced segregation of unmyelinated axons. This was evidenced by an increase in transgenic Remak bundles that enclosed just one to five axons (quantified in Fig. 6C) or with single-axon pockets (Fig. 6D) compared to WT bundles.

We also asked whether Akt activation is sufficient to convert unmyelinated, post-ganglionic sympathetic nerve fibers to a myelinated fate, akin to the effects of overexpressing Nrg1II in these axons (Taveggia et al., 2005). Examination of the sympathetic tract of transgenic mice (Fig. 6E) revealed that fibers were consistently unmyelinated. Instead, multiple layers of Schwann cell membrane surrounded the axons thus resembling the Remak bundles in the sciatic nerves and dorsal roots of the transgenic mice. Schwann cell pockets containing only extracellular matrix were also found in this tract (Fig. 6E).

In agreement with a lack of effect on myelination, the proportion of myelinated fibers in the dorsal and ventral roots of transgenic and wild type mice were comparable (Fig. 6F). Together, these data suggest that Akt regulates axonal wrapping and that other signals are required for myelination.

**MyrAkt specifically enhances Rac1 activity in Schwann cells**

Rac1 and cdc42 are crucial for proper sorting of axons at early stages of myelination; their precise roles differ as cdc42 controls the pool of Schwann cells by affecting proliferation whereas Rac1 induces radial lamellipodia required to sort axons (Benninger et al., 2007; Nodari et al., 2007). To assess whether the enhanced axonal sorting and wrapping observed in MyrAkt animals might reflect activation of Rac1 or cdc42, we induced MyrAkt in cultured
Schwann cells. Induction of Akt led to activation of Rac1 but not cdc42 based on pull-downs with GST-Pak1 (Fig. 7A, B); there was no change in total levels of either Rac1 or cdc42. This data suggests that part of the phenotype observed in the transgenic mice, such as enhanced Schwann cell sorting, is a consequence of increased Rac1 activity.

Transgenic nerves develop tomacula and myelin outfoldings/infoldings

A consistent finding in the MyrAkt sciatic nerves was the presence of numerous myelin abnormalities. These included myelin outfoldings, a histological hallmark of some Charcot-Marie-Tooth (CMT) forms, notably CMT4B (Bolis et al., 2005; Tersar et al., 2007), and tomacula, i.e. focal thickenings of the myelin sheath characteristic of Hereditary Neuropathy with Liability to Pressure Palsies (HNPP) (Adlkofer et al., 1997); tomacula were also seen in the PTEN conditional knockout mice (Goebbels et al., 2012). Five month-old nerves developed mostly myelin infoldings (Fig. 8A, left panel, and Fig. 8BII) and tomacula (Fig. 8A, right panel, and Fig. 8BI). These changes were preferentially located to regions of non-compacted myelin, i.e. the paranodes and Schmidt-Lanterman incisures. Tomacula were accompanied by axonal compression at the affected regions, although no axonal degeneration was detected at the ages examined (up to one year old). Other abnormalities such as myelin outfoldings were observed in a lower proportion of cases (Fig. 8BIII, C). Teased fibers from transgenic sciatic nerves also revealed presumptive tomacula, which were either symmetric (both sides of the affected node) or asymmetric (only one side affected, e.g. Fig. 8D). Similar asymmetry of hypermyelination was also observed (data not shown).

Rapamycin treatment prevents myelin abnormalities in vivo

The mTOR pathway has been previously implicated in the Akt-mediated hypermyelination in the CNS (Flores et al., 2008; Narayanan et al., 2009; Goebbels et al.,
In agreement, MyrAkt activates mTOR in the PNS based on Western blot analysis of sciatic nerve lysates. Increased phosphorylation of Akt at both the S473 or Th308 residues was readily detected in the transgenics by the appearance of an extra phosphorylated Akt band resulting from the myristoylation tag (Fig. 8E). A statistically significant increase of phospho-S6RP (S235/236) levels, an indirect substrate of mTORC1 and readout of Akt activation, was found in samples from transgenic animals when compared to their wild type littermates (Fig. 8E, F). The levels of phospho-GSK3b (S9) and the translation repressor protein phospho-4E-BP1 (Thr37/46) were also increased in those nerves, although did not reach statistical significance.

No significant differences were found for the total levels of any of these proteins (Fig. 8F). These results confirm that the CNP-MyrAktHA transgene is not only properly expressed, but also active in those animals.

Treatment with rapamycin for eight weeks resulted in a dramatic reduction in sciatic nerve size in MyrAkt mice (Fig. 9A, C) and a correction of hypermyelination (Fig. 9A). The efficacy of the rapamycin treatment on mTOR activity was corroborated by Western blot analysis (Fig. 9B). Other parameters affected in the MyrAkt transgenics, such as brain size or the number of myelin abnormalities, were also ameliorated by rapamycin treatment, and corrected to near wild type levels (Fig. 9C). In dorsal roots, g-ratios values were significantly increased in drug-treated versus vehicle-treated transgenics (0.59 +/- 0.02 and 0.54 +/- 0.01 respectively), although the values were still somewhat lower than their wild type littermates (0.62 +/- 0.006, Fig. 9D). Interestingly, no improvement of the hyperwrapping phenotype was detected in the Remak bundles of the rapamycin-treated transgenics (Fig. 9E). Taken together, our data indicates that mTOR activation has a key role in many but not all of the PNS phenotypes driven by activation of Akt.
DISCUSSION

PNS myelination is controlled by levels of axonal NRG1III (Michailov et al., 2004; Taveggia et al., 2005), which activates Schwann cell ErbB receptors and thereby PI3K, MAPK, and Phospholipase C-γ; each of these pathways have been implicated in myelination (Pereira et al., 2010; Pereira et al., 2012; Salzer, 2015). In the case of PI3K, pharmacological inhibition blocks myelination in vitro at an early stage (Maurel and Salzer, 2000) whereas PI3K gain of function, via conditional ablation of PTEN, results in hypermyelination in vivo with the occasional small caliber axon switching to a myelinated fate (Goebbels et al., 2010). The serine/threonine kinase Akt is a major effector of PI3K and is thus a candidate to mediate these effects in the PNS. However, a prior study of a transgenic mouse overexpressing Akt-DD in both oligodendrocytes and Schwann cells under the control of the glial promoter PLP, demonstrated hypermyelination in the CNS but not the PNS (Flores et al., 2008). This latter result raised the question of whether the effects of PI3K in the PNS are primarily mediated by Akt or result from Akt-independent signaling by PI3K (Ebi et al., 2013).

We now demonstrate that Akt is indeed a key regulator of PNS myelination based on both loss (perifosine treatment) and gain of function (transgene) analyses. The expression of a constitutively active Akt under control of the CNP promoter provides some striking similarities and interesting differences with previously reported animal models. In particular, our findings phenocopy important aspects of the PTEN conditional mice (Goebbels et al., 2010; Goebbels et al., 2012), while differing from the prior Akt transgenic mouse model (Flores et al., 2008). CNP comprises a higher percent of the total myelin protein in the PNS than does PLP (Patzig et al., 2011) indicating that the lack of a PNS effect in the previously reported PLP-AktDDD transgenic mice (Flores et al., 2008) may be due to lower expression levels. In addition, we observed a more consistent hypermyelinating phenotype in the MyrAkt than in the Akt-DD
transgenics, each under the control of the CNP promoter, suggesting the membrane-targeted form of Akt is more potent in promoting hypermyelination.

The promyelinating effect of Akt shown here is consistent with evidence that axonal NRG1III is the main driver of Akt activation (Taveggia et al., 2005; Heller et al., 2014). Indeed, overexpression of NRG1III also results in hypermyelination (Michailov et al., 2004) and our results suggest Akt activation likely strongly contributes. Myelin outfoldings/infoldings are also present in human mutations of MTMR13 in CMT patients and corresponding mouse models, that increase the levels of PIP4,5 (Bolis et al., 2005; Tersar et al., 2007; Robinson et al., 2008; Goebbels et al., 2012) which would not be expected to activate PI3K. Thus, other mechanisms can contribute to myelin outfoldings and tomacula in addition to hyper-activation of Akt. Interestingly, myelin outfoldings are normally present in the CNS at the peak of myelination as a consequence of active myelin production, correlated with an elevated concentration of PIP3 at the inner tongue of the process and the presence of cytoplasmic channels (Snaidero et al., 2014). These features disappear in mature CNS myelin.

Here we implicate Akt as a direct regulator of axonal sorting and wrapping, which are among the earliest events in axon-Schwann cell interactions. Thus, pharmacological reduction of Akt activity partially blocks wrapping (Fig. 2G) whereas MyrAkt leads to excessive wrapping in the transgenics, most evident in non-myelinating Schwann cells of Remak bundles and sympathetic fibers. A similar phenotype was also seen in PTEN conditional mice (Goebbels et al., 2010). A plausible candidate to mediate these effects is Rac1, which drives generation of radial lamellipodia in Schwann cells required for ensheathment of axons and the onset of myelination (Benninger et al., 2007; Nodari et al., 2007). PI3K activates its effectors, including Akt, by generating local concentrations of PIP3. PI3K similarly activates Rho GTPases, notably Rac, via PIP3-dependent activation of members of the Dbl family of guanine-nucleotide exchange factors (GEFs) (Innocenti et al., 2003). Results in this study (Fig. 7) indicate that Akt
can activate Rac1 independently of PIP3-dependent effect of PI3K on GEFs. They further suggest Akt-dependent activation of Rac1 may account for the hyperwrapping and hypermyelination observed in the PTEN conditional mice given the similarity of phenotypes.

Interestingly, the membrane outfoldings and Schwann cell pockets induced by MyrAkt were not obligately coupled to axonal contact; even collagen fibers were wrapped in the transgenic mice (Fig. 6AII). In normal nerves, Akt is activated initially along the internode, in close apposition to and dependent on NRG on the axon; activated Akt is later detected at the paranodes once compact myelin has formed (Heller et al., 2014). The NRG-dependent activation of Akt locally, along the inner turn, thus favors specific wrapping of the apposed axon. In contrast, the widespread activation of Akt along other membranes of the transgenic Schwann cells, likely supports wrapping that is independent of axonal contact. Remarkably, some of the Schwann cell processes lacking axonal contact were surrounded by basal lamina in the transgensics (Fig. 6A, B). These results suggest that Akt may help transduce the axonal signal that drives production and deposition of extracellular matrix components by Schwann cells (Bunge et al., 1986).

A striking result of this study is that the promyelinating effects of Akt are not correlated to the levels of Krox20, the key transcriptional driver of PNS myelination (Topilko et al., 1994). Thus, induction of MyrAkt in Schwann cell cultures resulted in an increase, with some variability, of myelin protein and mRNA levels despite a modest reduction in the basal levels of Krox20 (Fig. 3). Conversely, inhibition of Schwann cell Akt by Pf partially arrests ensheathment and nearly completely blocks myelin protein expression but not the upregulation of Oct6 and Krox20 (Fig. 2). In the latter case, partial ensheathment of axons may have been sufficient to upregulate these transcription factors whereas treatment with LY by completely abolishing ensheathment, may have thereby blocked Oct6 and Krox20 expression. Together, these results suggest that changes in myelin mRNA and protein levels resulting from Akt
inhibition/activation may not be transcriptionally regulated. Alternative possibilities include an effect of Akt on miRNAs or protein translation. Akt has been implicated in regulating miRNA levels via the FOXO transcription factors and MDM2/p53 activity (Xu and Mo, 2012); FOXO phosphorylation is indeed increased in the MyrAkt mice (E. Doménech-Estévez, data not shown) raising the potential of similar regulation of the Schwann cell phenotype via miRNAs (Pereira et al., 2010). In addition, Akt may control myelin protein levels by regulating their turnover and translation. A key role for translational control in myelination was shown by the rescue of myelination in ErbB deficient Schwann cells via expression of activated Mek1DD which, in turn, strikingly upregulated protein translation (Sheean et al., 2014). Like the MyrAkt transgenics, sciatic nerves in the activated Mek1 transgenic mice are hypermyelinated, with tomacular defects, and have small caliber axons that remain unmyelinated (Sheean et al., 2014). This latter result suggests that other signaling pathways downstream of NRG/ErbB activation, including the PLCγ/calcineurin/NFATc4 pathway (Kao et al., 2009), are also required for expression of the transcriptional phenotype of myelinating Schwann cells.

As in the PTEN mutants, the MyrAkt transgenics have increased mTORC1 activity, evidenced by increased phosphorylation of S6RP (Fig. 8). mTOR has a key role in Schwann cell myelination (Sherman et al., 2012). In particular, the mTORC1 complex links nutrient availability and cell growth by regulating protein and lipid synthesis (Porstmann et al., 2008; Laplante and Sabatini, 2009; Peterson et al., 2011). Mice deficient in the mTORC1 component raptor have delayed myelination and hypomyelination in the adult due to impaired RXRγ-SREBP controlled lipid biosynthesis (Norrmen et al., 2014); these results place mTORC1, and by implication Akt, as important coordinators of protein translation and lipid synthesis in the myelinating Schwann cells. Rapamycin administration dramatically reduces the pathological features of the MyrAkt transgenics, normalizing the g-ratios, number of axons per area, number of myelin abnormalities and brain weight (Fig. 9). These results corroborate the beneficial
effects of rapamycin in treating dysmyelinating pathologies resulting from deregulation of the PI3K-Akt-mTORC1 axis (Narayanan et al., 2009; Goebbels et al., 2012).

Interestingly, the hyperwrapping phenotype in the transgenics in unmyelinated Schwann cells was not blocked by rapamycin (Fig. 9E), presumably as hyperwrapping is driven by Rac1 and is independent of mTOR. Thus, Akt-induced wrapping and myelin production, although coordinated, are two distinct phenomena driven by independent pathways. Indeed, multiple crucial events of myelination, including morphogenesis (Benninger et al., 2007; Ozcelik et al., 2010), transcriptional activation (Zorick et al., 1996; Jacob et al., 2011), protein and lipid synthesis (Nadra et al., 2008; Norrmen et al., 2014) and metabolic status (Pooya et al., 2014) must all be tightly coordinated during Schwann cell myelination. Akt activation likely contributes to each of these events with the potential exception of Krox20-dependent transcriptional events.

In conclusion, we have shown that Akt has a key role in regulating PNS myelination, enhancing membrane wrapping potentially via Rac1 activation and myelin protein synthesis via mTORC1. These studies suggest that PI3K/Akt activation has a key role and cooperates with other signaling pathways during the shift from the ensheathing to the myelinating Schwann cell phenotype. Our data additionally suggest that myelin abnormalities in various neuropathies, including in/outfoldings and tomacula, may result from Akt activation and highlight Akt and its effectors, as potential therapeutic targets. Akt activation would be expected to ameliorate the phenotype of hypomyelinating peripheral neuropathies, e.g. CMT4C (Arnaud et al., 2009; Gouttenoire et al., 2013) whereas Akt inhibition would be a candidate to ameliorate tomacular defects in neuropathies such as HNPP (Sander et al., 2000; Goebbels et al., 2012). Further studies of Akt-dependent pathways in myelination may identify more specific therapeutic targets for these neuropathies in the future.
REFERENCES


replaces Nrg1/ErbB3 signals during Schwann cell development and myelination. Genes & development 28:290-303.


(PKB gamma/Akt3) in postnatal brain development but not in glucose homeostasis.

Development 132:2943-2954.


FIGURE LEGENDS

Figure 1. Loss of individual Akt isoforms in vivo does not affect PNS myelination.

A, Western blot analysis of the expression of the three Akt isoforms in dorsal root ganglia neurons (Neu), Schwann cells (SC), and non-myelinated (C) or myelinated (C+C) cocultures. Akt1 and Akt3 are preferentially expressed by neurons whereas Akt2 is primarily expressed by Schwann cells. n=3. SEM is shown. B, Semithin sections of sciatic nerves from two month-old mice deficient in each Akt isoform revealed no obvious defects of myelination. Left panels show a magnification of the inset from the semithin section. Right panels (a-f) show representative images of Remak bundles. No abnormalities of myelination or ensheathment were evident at the time point analyzed, although no quantifications were performed. Scale bars for semithin 100 µm, for EM 2 µm.

Figure 2. Akt inhibition blocks myelin formation in vitro without affecting Krox20 levels.

A, Treatment of DRG neuron-Schwann cell cocultures with perifosine (Pf) or LY294002 (LY) blocked myelination. The myelin transcription factors Krox20 and Oct6 continue to be robustly expressed by Schwann cells in the Pf but not the LY treated cocultures. n=5, four coverslips were analyzed for each n. B, Quantification of the blockade of myelination by Pf and LY. The average number of myelin segments per coverslip were: controls, 2195; Pf, 37 (p=0.0056); and LY, 3 segments (p=0.005). n=3, each n represents two coverslips. C,D, Pf treated cells showed no change in Krox20 protein expression (102.8 +/- 12.31, p=0.83), although a significant decrease in pAkt 473 (40.1 +/- 7.77, p=0.001), MBP (3.1 +/- 0.2, p<0.001) and P0 (12.5 +/- 4.49, p<0.001) was detected. The same markers were also downregulated in LY treated cocultures (pAkt 26.7 +/- 6.84, p<0.001; MBP 1.6 +/- 1.03, p<0.001; P0 1.69 +/- 0.68, p<0.001), but in this case Krox20 was also decreased (22.1 +/- 5.86, p<0.001) (n=3, each n represents eight coverslips pooled per condition). Western blot quantification data were normalized using
values from control cocultures that were arbitrarily set to 100. E, As detected by real time PCR, Pf treated cells showed no changes in Krox20 mRNA (1.27 +/- 0.39, p=0.51), and a significant decrease of mRNA for MBP (0.13 +/- 0.03, p<0.001). A decrease of P0 was also detected, although it did not reach statistical significance (0.62 +/- 0.18 p=0.09). These three markers were significantly downregulated in LY treated cocultures (Krox20 0.12 +/- 0.04, p<0.001; MBP 0.01 +/- 0.003, p<0.001; P0 0.23 +/- 0.06, p<0.001). Expression data was normalized to control samples that were arbitrarily set as 1; GAPDH expression was used as reference. n=4, four coverslips were pooled per condition for each n. F, Schwann cell proliferation was not affected by 20 µM of Pf (11.9 +/- 0.019 vs Control 11.2 +/- 0.02), whereas proliferation was almost absent with 20 µM of LY treatment (0.7 +/- 0.002, p=0.003). n=4, each n represents three coverslips per condition. G, EM analysis of control, Pf and LY treated cultures revealed drug-specific differences. In the presence of Pf, Schwann cells (SC) engaged axons (A) and partially but incompletely sorted them and failed to myelinate. LY treated Schwann cells completely failed to sort axons. The image depicts representative fields from the cultures shown in A. Scale bars: 1 µm. SEM is shown in all panels.

Figure 3. Akt activation promotes myelin formation independently of Krox20 regulation.

Purified Schwann cells infected with doxycycline (Dox) inducible lentiviruses encoding MyrAkt-HA or GFP were cultured in ascorbic acid containing media in the absence of axons. A, GFP induction with Dox did not affect the basal levels of protein for Krox20, P0 and MAG. Basal levels for MAG were not detectable for quantification. n=3. B, C Induction of MyrAkt substantially increased P0 protein levels (358.1, 586.7 and 1114.5 folds vs 100, average 686.5 +/- 223.98, p=0.058) and significantly increased MAG levels (3541.7, 9467.8 and 6717.2 folds vs 100, average 6575.6 +/- 1712.19, p=0.045), as detected by Western blot. Interestingly, a modest but significant reduction of Krox20 was also detected (83.8 +/- 5.28, p=0.037). Western
blot quantification data were normalizing by using values from control samples that were arbitrarily set to 100. n=3. SEM is shown. D, Krox20 mRNA expression remained unchanged (0.77 +/- 0.19, p=0.27) when Akt was induced with doxycycline. mRNA for P0 and MAG were increased when Akt was induced, although due to the variability of induction (P0 1.7, 3.5 and 1.9 folds versus 1, average 2.4 +/- 0.57, p=0.07, and MAG 17.9, 168.9 and 42.2 folds versus 1, average 76.3 +/- 46.81, p=0.18) compared to the non-induced, the increase in these markers did not achieve significance by the T-test. Real time PCR data were normalized by using values from control samples that were arbitrarily set to 1. GAPDH was used as a reference. n=3. SEM is shown.

**Figure 4. Constitutively active Akt promotes CNS and PNS hypermyelination.**

A, Scheme illustrating the two constitutively active Akt1 constructs driven by the CNP promoter that were used to establish transgenic mice. B, The HA-tagged construct was weakly detectable in E13.5 dorsal root ganglia isolated from transgenic mice and readily detectable in sciatic nerves (SN) from P0.5 until adulthood, with a peak at P10 that correlates with active myelination. C, One-year-old transgenic mice carrying the MyrAkt transgene developed enlarged neural structures. Optic nerves (asterisk indicates the optic chiasm), brains, and sciatic nerves were all enlarged. D, HA was detectable in satellite cells from 2 month-old mouse dorsal root ganglia without any obvious presence in neurons. In 2 month-old sciatic nerves, HA was present with variable intensity in Schwann cells. Scale bars 20 µm. E, Four month-old transgenic brains (MyrAkt) were bigger than wild types (WT), with a thicker corpus callosum (delineated in blue) and increased MBP staining, evidence of enhanced myelination. Scale bar 1 mm.

**Figure 5. Nerves from transgenic mice are hypermyelinated.**
A, At five months, sciatic and optic nerves from MyrAkt transgenics were enlarged compared to wild types (WT) mice, as seen in transverse, toluidine blue stained sections (scale bar 100 µm).

B, EM sections show thicker myelin sheaths in 5 month-old MyrAkt and AktDD sciatic nerves. Optic nerves from MyrAkt were also hypermyelinated. Scale bar: sciatic nerve 10 µm, optic nerve 2 µm. C, The myelin sheaths in transgenic nerves had increased numbers of myelin lamellae, scale bar 1 µm; higher magnification revealed no change in the periodicity of the myelin lamellae, scale bar 100 nm. D, g-ratio analysis revealed hypermyelination was more pronounced in small caliber axons (0.5 to 2 microns). E, Average g-ratio in the transgenic dorsal root was lower than in wild types (0.62 +/- 0.01 vs 0.67 +/- 0.01 respectively, p=0.02).

250 - 300 axons between 0.5 to 8 microns were measured. This difference was accentuated when only small caliber axons (0.5 to 2 microns) were considered (0.52 +/- 0.004 vs 0.61 +/- 0.01, p=0.002). n=3. SEM shown. F, The numbers of Schwann cell nuclei were comparable in WT and MyrAkt dorsal roots (216 +/- 9.7 vs 250 +/- 29.2, respectively) and ventral roots (82 +/- 5.5 vs. 94 +/- 8.1, respectively) from 5 months old animals. n = 4. SEM is shown.

**Figure 6.** Activated Akt enhances wrapping and sorting but not myelination of axons in Remak Schwann cells.

A, EM micrographs from 20 month-old mice reveal aberrant axon-Schwann cell relationships in Remak bundles in transgenic compared to WT mice. Small axons were often surrounded by circumferential layers of uncompacted Schwann cell membranes (I, shown at higher magnification in insert). Schwann cell membranes surrounding collagen fibers (II) were also present in the transgenic nerves and were frequently covered by basal lamina. Scale bar 1 µm.

B, In 5 month old-mice, Schwann cell processes (I), with associated basal lamina without apparent axonal contact are present; arrowheads demarcate basal lamina deposition. Schwann cells also formed empty pockets with basal lamina deposited in the interior (II arrow in the
insert); scale bars 2 μm. C, Bar graph showing the distribution of the numbers of axons per Schwann cell; Remak bundles with only a few axons (1-5) are increased in the 5 month-old transgenic mice. D, The number of axons per pocket was also decreased in the 5 month-old Tg suggesting better segregation of axons (one axon per pocket WT 89.12 +/- 0.007 vs Tg 96.12 +/- 1.17, p=0.027; two to ten axons WT 10.59 +/- 0.28 vs Tg 3.83 +/- 1.22, p=0.03; eleven to twenty axons WT 0.28 +/- 0.28 vs Tg 0.04 +/- 0.04, not significant). n=2, 100 bundles from sciatic nerves were analyzed per animal. E, Electron micrographs of the sympathetic tract from 20 month-old mice are shown. No myelinated fibers are present but multilamellamellar wrapping of axons and collagen fibrils are seen consistent with a role of Akt in wrapping. Scale bar 500 nm. F, The numbers of myelinated axons in transgenic dorsal (DR) and ventral (VR) roots at 5 months were not statistically different in MyrAkt vs WT mice; n=2. SEM is shown in panels D and F.

Figure 7. MyrAkt induces Rac1 activity in cultured Schwann cells. 
A, Western blot showing the controls (GDP, GTPγS and GST) as well as samples from non-induced (-DOX) and doxycycline-induced (+DOX) Schwann cell pools transfected with the MyrAkt construct. The same –DOX and +DOX samples were loaded into two consecutive lines. B, Quantification of Rac1 and cdc42 levels. Values shown represent active GTPase levels divided by total GTPase levels and corrected for actin, which served as a loading control. All data were normalized to non-induced controls, which were set to 100. Induction of MyrAkt by addition of doxycycline to the culture media increased Rac1 activity significantly (193 +/- 25.31, p=0.01) but not cdc42 (96.82 +/- 27.11, p=0.91). After correction for total cdc42 and loading amounts, the level of active cdc42 in panel A is not significantly increased. SEM is shown. Rac1: n=4 independent sets of experiments, cdc42: n=3 independent sets of experiments.
Figure 8. Sciatic nerves of MyrAkt transgenic mice exhibit tomacular defects and activation of mTOR.

A, Upper panels: Longitudinal electron micrographs of sciatic nerves from five month-old WT animals. Nodes are indicated by asterisk and the clefts by arrows. Lower panels: Longitudinal electron micrographs of sciatic nerves from transgenic animals reveal myelin infolding at the paranodes (left panel) and tomacula near the clefts (indicated with arrows) resulting in compression of the axon (right panel). Scale bars 5 µm. B, Example of the different myelin abnormalities observed in sciatic nerves: I, tomacula, showing compression of the axon; II, infolding and III, outfolding. Scale bars 5 µm. C, Percentages for each of the major myelin abnormalities found in cross-sections from 3 months-old transgenic sciatic nerves. n=3. D, Teased fibers from six-month-old transgenic mice show an example of an asymmetric tomacular defect with enlargement in the paranodal region of the left myelin sheath but not the right myelin sheath (asterisk marks node). E, Western blot analysis of extracts from nerves from 2 month-old WT and transgenic mice show activation of the mTOR pathway. F, Quantification of Western blots demonstrates phosphorylated S6RP is increased in Tg nerves (218.4 +/- 25.79, p=0.01) and the ratio of phosphorylated to total S6RP is also increased (167.1 +/- 16.04, p=0.014); data were normalized to WT values arbitrarily set to 100. Increased phosphorylation of GSK3b and 4EBP1 were also evident but did not reach statistical significance. n=3. SEM is shown.

Figure 9. Rapamycin treatment reduces myelin abnormalities in CNP-MyrAkt transgenic mice.

A, The phenotype of three month-old transgenic mice was largely corrected by treatment with rapamycin for eight weeks (MyrAkt+Rapa) but not by vehicle (MyrAkt+vehi); no changes were detected in control animals treated with vehicle (WT+Vehi). B, Phosphorylation of S6RP was
substantially decreased in the nerves of WT and MyrAkt mice treated with rapamycin. C, Analysis of several parameters are shown for WT mice treated with vehicle, and for transgenics (Myc) treated either with vehicle or rapamycin. These include brain weight (WT+Vehi 393 mg +/- 6.3; Myr+Vehi 438 +/- 10.2, p=0.019; Myr+Rapa 371 +/- 4.75, p=0.004), the number of axons per 100 µm² (WT+Vehi 3.4 +/- 0.2; Myr+Vehi 2.3 +/- 0.07, p=0.01; Myr+Rapa 3.6 +/- 0.18, p=0.002) and the ratio of myelin abnormalities (i.e. tomacula and myelin in/outfoldings)/total axons counted (WT+Vehi 0.2% defect +/- 0.03; Myr+Vehi 3.6% +/- 0.6, p=0.003; Myr+Rapa 0.67% +/- 0.14, p=0.006). n=3. More than 3000 axons per n were examined to obtain the percentage of abnormalities. SEM is shown. D, G-ratios were measured for small myelinated fibers in the dorsal roots of wild type mice on vehicle (WT+V), transgenics on Vehicle (Myc+V) and transgenics treated with rapamycin (Myc+R). Quantification of WT+Vehi (0.62 +/- 0.006), Myr+Vehi (0.54 +/- 0.01, p<0.001) and Myr+Rapa (0.59 +/- 0.02, p=0.048) demonstrates a significant increase in the g-ratio of transgenic mice treated with rapamycin. 112 - 175 small caliber axons (0.5 to 2 µm) were measured per condition. n=4. SEM is shown. E, Rapamycin administration does not prevent the excess of membrane wrapping in the Remak bundles from 3 months old MyrAkt nerves. Schwann cells are pseudocolored in yellow and axons in the bundle in blue. Scale bar 1 µm.